429 related articles for article (PubMed ID: 23645227)
21. Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam
Azar G; Quaranta-El Maftouhi M; Masella JJ; Mauget-Faÿsse M
J Fr Ophtalmol; 2017 Apr; 40(4):303-313. PubMed ID: 28336284
[TBL] [Abstract][Full Text] [Related]
22. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9.
Age-Related Eye Disease Study Research Group
Arch Ophthalmol; 2001 Oct; 119(10):1439-52. PubMed ID: 11594943
[TBL] [Abstract][Full Text] [Related]
23. Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids.
Wolf-Schnurrbusch UE; Zinkernagel MS; Munk MR; Ebneter A; Wolf S
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8069-74. PubMed ID: 26720458
[TBL] [Abstract][Full Text] [Related]
24. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.
Dawczynski J; Jentsch S; Schweitzer D; Hammer M; Lang GE; Strobel J
Graefes Arch Clin Exp Ophthalmol; 2013 Dec; 251(12):2711-23. PubMed ID: 23695657
[TBL] [Abstract][Full Text] [Related]
25. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls.
Richer S; Devenport J; Lang JC
Optometry; 2007 May; 78(5):213-9. PubMed ID: 17478338
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
Csader S; Korhonen S; Kaarniranta K; Schwab U
Nutrients; 2022 Oct; 14(20):. PubMed ID: 36296956
[No Abstract] [Full Text] [Related]
27. A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3.
; Maraini G; Williams SL; Sperduto RD; Ferris F; Milton RC; Clemons TE; Rosmini F; Ferrigno L
Ophthalmology; 2008 Apr; 115(4):599-607.e1. PubMed ID: 18387406
[TBL] [Abstract][Full Text] [Related]
28. Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.
Ramkumar HL; Tuo J; Shen DF; Zhang J; Cao X; Chew EY; Chan CC
J Nutr; 2013 Jul; 143(7):1129-35. PubMed ID: 23677863
[TBL] [Abstract][Full Text] [Related]
29. Plasma lutein and zeaxanthin and the risk of age-related nuclear cataract among the elderly Finnish population.
Karppi J; Laukkanen JA; Kurl S
Br J Nutr; 2012 Jul; 108(1):148-54. PubMed ID: 22005336
[TBL] [Abstract][Full Text] [Related]
30. Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration.
Robman L; Vu H; Hodge A; Tikellis G; Dimitrov P; McCarty C; Guymer R
Can J Ophthalmol; 2007 Oct; 42(5):720-6. PubMed ID: 17724493
[TBL] [Abstract][Full Text] [Related]
31. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative.
Moeller SM; Parekh N; Tinker L; Ritenbaugh C; Blodi B; Wallace RB; Mares JA;
Arch Ophthalmol; 2006 Aug; 124(8):1151-62. PubMed ID: 16908818
[TBL] [Abstract][Full Text] [Related]
32. A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract.
Ma L; Hao ZX; Liu RR; Yu RB; Shi Q; Pan JP
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):63-70. PubMed ID: 24150707
[TBL] [Abstract][Full Text] [Related]
33. Plasma long-chain omega-3 polyunsaturated fatty acids and macular pigment in subjects with family history of age-related macular degeneration: the Limpia Study.
Merle BMJ; Buaud B; Korobelnik JF; Bron A; Delyfer MN; Rougier MB; Savel H; Vaysse C; Creuzot-Garcher C; Delcourt C
Acta Ophthalmol; 2017 Dec; 95(8):e763-e769. PubMed ID: 28271618
[TBL] [Abstract][Full Text] [Related]
34. The effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers.
Graydon R; Hogg RE; Chakravarthy U; Young IS; Woodside JV
Br J Nutr; 2012 Jul; 108(2):334-42. PubMed ID: 22313522
[TBL] [Abstract][Full Text] [Related]
35. Association between lutein and zeaxanthin status and the risk of cataract: a meta-analysis.
Liu XH; Yu RB; Liu R; Hao ZX; Han CC; Zhu ZH; Ma L
Nutrients; 2014 Jan; 6(1):452-65. PubMed ID: 24451312
[TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Age-Related Eye Disease Study Research Group
Arch Ophthalmol; 2001 Oct; 119(10):1417-36. PubMed ID: 11594942
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973.
Richer SP; Stiles W; Graham-Hoffman K; Levin M; Ruskin D; Wrobel J; Park DW; Thomas C
Optometry; 2011 Nov; 82(11):667-680.e6. PubMed ID: 22027699
[TBL] [Abstract][Full Text] [Related]
38. The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older.
Khachik F; de Moura FF; Chew EY; Douglass LW; Ferris FL; Kim J; Thompson DJ
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5234-42. PubMed ID: 17122108
[TBL] [Abstract][Full Text] [Related]
39. Nutritional supplementation in age-related macular degeneration.
Coleman H; Chew E
Curr Opin Ophthalmol; 2007 May; 18(3):220-3. PubMed ID: 17435429
[TBL] [Abstract][Full Text] [Related]
40. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
